PMN310 has been granted Fast Track Designation by the U.S. FDA for the treatment of Alzheimer’s disease.
Company Profile
ProMIS™ Neurosciences, Inc. (Nasdaq: PMN), is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD). The Company has offices in Toronto, Ontario, and Cambridge, Massachusetts.